These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 36102932)
1. CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature. Karam A; Mjaess G; Martinez Chanza N; Aoun F; Bou Kheir G; Younes H; Kazzi H; Albisinni S; Roumeguère T Cancer Invest; 2022 Nov; 40(10):923-937. PubMed ID: 36102932 [TBL] [Abstract][Full Text] [Related]
2. Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions. Mishra A; Maiti R; Mohan P; Gupta P Eur J Haematol; 2024 Feb; 112(2):211-222. PubMed ID: 37705357 [TBL] [Abstract][Full Text] [Related]
3. Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions. Taylor MR; Steineck A; Lahijani S; Hall AG; Jim HSL; Phelan R; Knight JM Transplant Cell Ther; 2023 Jan; 29(1):19-26. PubMed ID: 36208728 [TBL] [Abstract][Full Text] [Related]
4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292 [TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. Hsu J; Yang Y; Gergis M; Bi X; Yi D; Gergis U Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):94-99. PubMed ID: 36537910 [TBL] [Abstract][Full Text] [Related]
7. INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies-Established Findings and Future Priorities. Ligon JA; Ramakrishna S; Ceppi F; Calkoen FGJ; Diorio C; Davis KL; Jacoby E; Gottschalk S; Schultz LM; Capitini CM Transplant Cell Ther; 2024 Feb; 30(2):155-170. PubMed ID: 37863355 [TBL] [Abstract][Full Text] [Related]
8. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. Hauth F; Ho AY; Ferrone S; Duda DG JAMA Oncol; 2021 Jul; 7(7):1051-1059. PubMed ID: 33885725 [TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023. Sun MY; Li W; Chen W Hum Vaccin Immunother; 2023 Aug; 19(2):2251839. PubMed ID: 37814513 [TBL] [Abstract][Full Text] [Related]
10. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells. Abken H Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803 [TBL] [Abstract][Full Text] [Related]
11. Quality Assessment of Pre-Clinical Studies of Chimeric Antigen Receptor T-Cell Therapy Products: A Point of Focus on Safety. Maharshi V; Diksha D; Gupta P Curr Drug Saf; 2022; 17(2):129-135. PubMed ID: 34323195 [TBL] [Abstract][Full Text] [Related]
12. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932 [TBL] [Abstract][Full Text] [Related]
13. [Indications for CAR-T cell therapy and management of the complications: an update]. Di Lorenzo S; Errichiello S; Cerne D; Venturini M; Visintini C Assist Inferm Ric; 2022; 41(4):195-211. PubMed ID: 37283174 [TBL] [Abstract][Full Text] [Related]
14. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy. Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476 [TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
16. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review]. Fang Z; Han H; Liang L Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572 [TBL] [Abstract][Full Text] [Related]
17. Advanced Materials and Delivery Systems for Enhancement of Chimeric Antigen Receptor Cells. Li T; Luo R; Su L; Lv F; Mei L; Yu Y Small Methods; 2023 Nov; 7(11):e2300880. PubMed ID: 37653606 [TBL] [Abstract][Full Text] [Related]